B. Riley Securities Maintains Buy on Orchestra BioMed Hldgs, Lowers Price Target to $10
Orchestra Biomed Holdings Inc OBIO
$4.13
▲ +0.73%
(+$0.03)
Open
$4.09
Prev Close
$4.10
Day Range
$4.09 – $4.14
52W Range
$2.20 – $5.42
Market Cap
$246.71M
Beta
0.53
EPS (TTM)
$-1.29
📋 Company Profile
| Industry | Health Care |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2020-08-04 |
| Shares Out. | 59,880,000 |
| Website | orchestrabiomed.com ↗ |
| Phone | 16463439298 |
Orchestra Biomed Holdings Inc is a publicly traded company under the ticker symbol OBIO on the NASDAQ NMS - GLOBAL MARKET, operating in the Health Care industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
14 analysts (2026-05-01)
📰 Latest News for OBIO
HC Wainwright & Co. Reiterates Buy on Orchestra BioMed Hldgs, Maintains $10 Price Target
Barclays Maintains Overweight on Orchestra BioMed Hldgs, Raises Price Target to $13
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Lags Revenue Estimates
Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates
Orchestra BioMed Hldgs Q1 EPS $(0.33) Beats $(0.41) Estimate, Sales $110.000K Miss $190.750K Estimate
Orchestra BioMed Targeting BACKBEAT Trial Enrollment Completion By End of Q3 2026 and Data Presentation in Q2 2027
Orchestra BioMed Plans To Complete Enrollment In Its BACKBEAT Study Of Atrioventricular Interval Modulation Therapy By End Of Q3; Plans To Submit Primary Endpoint Data With Medtronic In Q2